Page numbers refer to the print edition but are hyperlinked to the appropriate location in the e-book.
age, as health risk factor 59–62
Agouti viable yellow mouse 122
alpha satellite repeats 66
adding to protein chain 146–9
amyotrophic lateral sclerosis (ALS) 235–6, 276
assisted reproductive technologies 141–3
brain
genes never expressed 176
brain tumours
see also individual diseases
cancer cells, telomerase activity 53
carbon monoxide levels 214
cats
tortoiseshell/calico patterning 94–5
Celera Genomics (company) 25, 29
Charcot-Marie-Tooth disease 44
chromosomes
chronic psychological stress 61
cigarette smoke, exposure to 213–14
collagens, defects in 220
congenital diarrhoea disorder 243–4, 330
Cornelia de Lange syndrome 169, 330
cytomegalovirus (CMV) 278
diabetes
genetics contribution in 212
Diamond-Blackfan Anaemia 150
DNA
DNA methyltransferases 134
DUX4 (FSHD retrogene) 284–6
chromosome numbers 64, 80
electron transport chain 154
evolutionary conclusions 195–9
measures of function 191–4
endogenous retroviruses (ERVs) 41–3
epigenetic modifications and 160–7
epigenetic modifications 114
ETMR paediatric brain tumour 330
evolution, ENCODE project and 195–9
expressivity, variable 206
extracellular matrix 50–1
familial hypercholesterolaemia 279–80
FOXP3 transcription factor 234
fruit flies, HOX cluster 41
gain-of-function mutations 230
gametes
GATA8 transcription factor 207
gender, determination 81–2
gene expression
amplification steps 14–16
stochastic component 88–9
genes, protein-coding, identification 98
genome
percentage having function 186–7
potential versus actual functional regions 191–4
genome-wide association studies (GWAS) 213
GlaxoSmithKline (company) 252–4
heart disease, obesity and 61
human cartilage-hair hypoplasia 257–8, 330
percentage having function 186–7
potential versus actual functional regions 191–4
Human GenomeProject 12, 26
human genome sequence
human immunodeficiency virus (HIV) 41, 244, 279
human telomere syndromes 55
idiopathic pulmonary fibrosis 56, 331
immunologically privileged sites 285
resetting the imprint 133–6
induced pluripotent stem (iPS) cells 164
infection, risk in elderly 54
infertility treatment 141–3
inflammatory response 160
interspersed repetitive elements 38–41
Japan, diet and longevity 62
Klinefelter’s syndrome 332
liver, and detoxification 275–6
Lou Gehrig’s disease (amyotrophic lateral sclerosis) 235–6, 276
macromolecular complex 146
marsupials, imprinted genes 130
untranslated regions at end of 232–6
mice
with Fragile X syndrome 229
gene knockout experiments 260–1
reconstituted eggs experiments 126–8, 135
Mirna Therapeutics (company) 275–6
and facial development 204–7
motor neuron disease (amyotrophic lateral sclerosis) 235–6, 276
Muscleblind-like protein 1 (MBNL1) 230
mutations
National Institutes of Health 25
non-templated changes 235
North American eastern equine encephalitis virus 268–9, 331
Opitz-Kaveggia syndrome 163, 331
organismal complexity, proportion of junk DNA and 4, 187–8
osteogenesis imperfecta (brittle bone disease) 219–25, 332
pancreas, development 209
papillary thyroid cancer 108
patient-derived cells 165
Polycomb Response Complex (PRC2) 118
positive feedback loops 166
proteins
pseudoautosomal regions 182
PTF1A transcription factor 207
RaNA Therapeutics (company) 281
red–green colour blindness 90
retina, viral infection in 278–9
ribosomal RNA molecules see rRNA
in primitive organisms 151
rodents, repeat elements in 40
simple sequence repeats 45–6
Six3 transcription factor 205
small interfering RNA (siRNA) 256
small molecule drugs 271–3
epigenetic modifications 267
Sonic Hedgehog (SHH) protein 202
chromosome numbers 64, 80
manipulating for therapeutic gain 248–54
supratentorial neuroectodermal tumours 266
Treacher-Collins Syndrome 150
variable expressivity 206
Williams-Beuren syndrome 44
worms
physical conformation 83–4
X inactivation centre 84, 88